CCR5 Antagonist Development Meeting Postponed
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and the Forum for Collaborative HIV Research have postponed a meeting to discuss CCR5 antagonist development until February or March in order to analyze new data